Loading...
OTCM
NWBO
Market cap302mUSD
Jul 09, Last price  
0.18USD
1D
-3.34%
1Q
-11.08%
Jan 2017
-48.91%
IPO
-99.78%
Name

Northwest Biotherapeutics Inc

Chart & Performance

D1W1MN
OTCM:NWBO chart
P/E
—
P/S
212.10
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.97%
Rev. gr., 5y
1.31%
Revenues
1m
-0.29%
80,00010,00010,00010,00010,00010,000772,000809,0001,454,0001,739,000623,000336,000412,0002,410,0001,291,0001,005,0001,683,0001,932,0001,382,0001,378,000
Net income
-61m
L-26.62%
-1,395,000-21,247,000-22,331,000-25,271,000-27,368,000-32,830,000-67,320,000-65,789,000-135,634,000-114,741,000-80,214,000-73,143,000-35,794,000-20,812,000-529,821,000179,126,000-105,032,000-62,599,000-83,778,000-61,477,000
CFO
-45m
L-21.49%
-6,930,000-14,601,000-15,587,000-4,677,000-6,376,000-14,707,000-22,754,000-37,800,000-54,576,000-78,608,000-55,652,000-36,495,000-34,586,000-31,859,000-32,093,000-38,299,000-52,775,000-53,637,000-57,017,000-44,763,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
URL
https://nwbio.com/
IPO date
Dec 14, 2001
Employees
22
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT